KR101761709B1 - 부위 특이적 통합 - Google Patents

부위 특이적 통합 Download PDF

Info

Publication number
KR101761709B1
KR101761709B1 KR1020157000511A KR20157000511A KR101761709B1 KR 101761709 B1 KR101761709 B1 KR 101761709B1 KR 1020157000511 A KR1020157000511 A KR 1020157000511A KR 20157000511 A KR20157000511 A KR 20157000511A KR 101761709 B1 KR101761709 B1 KR 101761709B1
Authority
KR
South Korea
Prior art keywords
gene
cell
nucleotide sequence
host cell
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157000511A
Other languages
English (en)
Korean (ko)
Other versions
KR20150029693A (ko
Inventor
제임스 랜스
로버트 영
마이클 제이. 아고스티노
마크 모펫
린 장
바오홍 장
Original Assignee
론자 바이올로직스 피엘씨
화이자 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 론자 바이올로직스 피엘씨, 화이자 인크. filed Critical 론자 바이올로직스 피엘씨
Publication of KR20150029693A publication Critical patent/KR20150029693A/ko
Application granted granted Critical
Publication of KR101761709B1 publication Critical patent/KR101761709B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020157000511A 2012-06-22 2013-06-20 부위 특이적 통합 Active KR101761709B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261663147P 2012-06-22 2012-06-22
US61/663,147 2012-06-22
EP12185330.3 2012-09-21
EP12185330.3A EP2711428A1 (en) 2012-09-21 2012-09-21 Site-specific integration
PCT/EP2013/062859 WO2013190032A1 (en) 2012-06-22 2013-06-20 Site-specific integration

Publications (2)

Publication Number Publication Date
KR20150029693A KR20150029693A (ko) 2015-03-18
KR101761709B1 true KR101761709B1 (ko) 2017-07-26

Family

ID=46888327

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157000511A Active KR101761709B1 (ko) 2012-06-22 2013-06-20 부위 특이적 통합

Country Status (18)

Country Link
US (2) US10280436B2 (cg-RX-API-DMAC7.html)
EP (2) EP2711428A1 (cg-RX-API-DMAC7.html)
JP (1) JP6053923B2 (cg-RX-API-DMAC7.html)
KR (1) KR101761709B1 (cg-RX-API-DMAC7.html)
CN (1) CN104379753B (cg-RX-API-DMAC7.html)
AU (1) AU2013279333C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014032299B1 (cg-RX-API-DMAC7.html)
CA (1) CA2876280C (cg-RX-API-DMAC7.html)
DK (1) DK2864489T3 (cg-RX-API-DMAC7.html)
EA (1) EA034039B1 (cg-RX-API-DMAC7.html)
ES (1) ES2629509T3 (cg-RX-API-DMAC7.html)
IL (1) IL236347A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02518A (cg-RX-API-DMAC7.html)
MX (1) MX351727B (cg-RX-API-DMAC7.html)
PL (1) PL2864489T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201408576QA (cg-RX-API-DMAC7.html)
TW (1) TWI523946B (cg-RX-API-DMAC7.html)
WO (1) WO2013190032A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210144430A (ko) 2020-05-22 2021-11-30 인천대학교 산학협력단 Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
HUE050105T2 (hu) * 2015-04-27 2020-11-30 Momenta Pharmaceuticals Inc Eljárás terápiás protein gyártására
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
EP3445781A1 (en) 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
SG10202010156XA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
JP7637470B2 (ja) * 2017-02-17 2025-02-28 ロンザ リミテッド アデノ随伴ウイルスを生産するための哺乳動物細胞
US20200002727A1 (en) * 2017-02-17 2020-01-02 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins
GB201703418D0 (en) * 2017-03-03 2017-04-19 Ge Healthcare Bio Sciences Ab Method for cell line development
EP3596206A1 (en) 2017-03-16 2020-01-22 Pfizer Inc Tyrosine prototrophy
CN107557390A (zh) * 2017-09-18 2018-01-09 江南大学 一种筛选cho细胞系高表达位点的方法
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
US20220049275A1 (en) * 2018-10-01 2022-02-17 Lonza, Ltd. Ssi cells with predictable and stable transgene expression and methods of formation
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
SG11202110076PA (en) 2019-04-02 2021-10-28 Chugai Pharmaceutical Co Ltd Method of introducing target-specific foreign gene
EP4058583A1 (en) 2019-11-14 2022-09-21 Lonza Ltd. Methods of cell selection
JP2023535604A (ja) 2020-07-30 2023-08-18 ファイザー・インク 遺伝子複製を有する細胞およびその使用
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
KR20240099288A (ko) 2021-10-18 2024-06-28 리제너론 파마슈티칼스 인코포레이티드 아데노바이러스-연관 바이러스 폴리뉴클레오티드를 포함하는 진핵세포
EP4473096A1 (en) 2022-02-02 2024-12-11 Pfizer Inc. Cysteine prototrophy
CN119955730A (zh) * 2023-11-08 2025-05-09 深圳太力生物技术有限责任公司 一种细胞株及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
CA2797661C (en) 1997-04-24 2015-06-16 University Of Washington Targeted gene modification by parvoviral vectors
BRPI0513706A (pt) * 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
JP4665115B2 (ja) * 2004-08-06 2011-04-06 独立行政法人理化学研究所 骨・関節疾患感受性遺伝子およびその用途
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zhang, C et al., Human Gene Therapy, 2007, vol.18, no.9, pp.787-797

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210144430A (ko) 2020-05-22 2021-11-30 인천대학교 산학협력단 Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포

Also Published As

Publication number Publication date
SG11201408576QA (en) 2015-03-30
EP2864489B1 (en) 2017-03-29
AU2013279333A1 (en) 2015-02-12
IL236347A0 (en) 2015-02-26
BR112014032299B1 (pt) 2021-09-21
TWI523946B (zh) 2016-03-01
PL2864489T3 (pl) 2017-09-29
JP2015519914A (ja) 2015-07-16
AU2013279333B2 (en) 2017-03-30
WO2013190032A1 (en) 2013-12-27
CN104379753B (zh) 2020-06-09
KR20150029693A (ko) 2015-03-18
CN104379753A (zh) 2015-02-25
US11326185B2 (en) 2022-05-10
EP2711428A1 (en) 2014-03-26
TW201420762A (zh) 2014-06-01
DK2864489T3 (en) 2017-07-17
HK1202580A1 (en) 2015-10-02
IN2014MN02518A (cg-RX-API-DMAC7.html) 2015-07-17
MX2014015612A (es) 2015-07-14
AU2013279333B9 (en) 2017-06-29
ES2629509T3 (es) 2017-08-10
US20150167020A1 (en) 2015-06-18
CA2876280C (en) 2018-02-06
BR112014032299A2 (pt) 2017-08-01
JP6053923B2 (ja) 2016-12-27
MX351727B (es) 2017-10-26
EA034039B1 (ru) 2019-12-20
US10280436B2 (en) 2019-05-07
EP2864489A1 (en) 2015-04-29
US20190119702A1 (en) 2019-04-25
EA201590068A1 (ru) 2015-04-30
CA2876280A1 (en) 2013-12-27
AU2013279333C1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
KR101761709B1 (ko) 부위 특이적 통합
US11965012B2 (en) Compositions and methods for TCR reprogramming using fusion proteins
CN110023500B (zh) 作为选择标记的减毒谷氨酰胺合成酶
US20030186841A1 (en) Ligand activated transcriptional regulator proteins
US20030119104A1 (en) Chromosome-based platforms
CN113396222A (zh) 腺相关病毒(aav)生产细胞系和相关方法
US20240207318A1 (en) Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
AU2017352591B2 (en) A two-part device for T-cell receptor synthesis and stable genomic integration to TCR-presenting cells
AU2016378480A1 (en) Endothelium-specific nucleic acid regulatory elements and methods and use thereof
KR20230019063A (ko) C9orf72 연관 질환의 치료를 위한 삼중 기능 아데노-연관 바이러스 (aav) 벡터
CN112877292A (zh) 产生人抗体的细胞
KR20240021906A (ko) 발현 벡터, 박테리아 서열-무함유 벡터, 및 이를 제조하고 사용하는 방법
KR20230117327A (ko) 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
CN114786685B (zh) 一种基于线粒体的药物递送系统及其用途
KR20240022571A (ko) Rna-가이드된 이펙터 동원을 위한 시스템, 방법 및 성분
CN117881788A (zh) 表达载体、无细菌序列载体及其制备和使用方法
CA2522166C (en) Lambda integrase mutein for use in recombination
HK40049685A (en) Adeno-associated virus (aav) producer cell line and related methods

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9